Piqray 200 mg film-coated tablets

DRUG3 trials

Sponsors

F. Hoffmann-La Roche AG, Oslo University Hospital HF, BOOG Study Center B.V.

Conditions

Breast cancerCancerMetastatic breast cancer

Phase 2

Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway

RecruitingCTIS2023-507894-16-00

Oslo University Hospital HFCancer

Start: 2021-04-01Target: 6000Updated: 2026-01-22

SEQUence of Endocrine therapy in advanced Luminal Breast cancer (SEQUEL-Breast): A phase 2 study on fulvestrant beyond progression in combination with alpelisib for PIK3CA-mutated, hormone-receptor positive HER2 negative advanced breast cancer

Active, not recruitingCTIS2024-514965-20-00

BOOG Study Center B.V.Breast cancer

Start: 2022-06-02Target: 130Updated: 2024-09-11

Phase 3

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS FULVESTRANT VERSUS ALPELISIB PLUS FULVESTRANT IN PATIENTS WITH HORMONE RECEPTOR- POSITIVE, HER2-NEGATIVE, PIK3CA MUTATED, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO PROGRESSED DURING OR AFTER CDK4/6 INHIBITOR AND ENDOCRINE COMBINATION THERAPY

Active, not recruitingCTIS2022-502322-41-00

F. Hoffmann-La Roche AGMetastatic breast cancer

Start: 2023-09-12Target: 150Updated: 2025-12-03